www.QualityStocks.Net would like to highlight Cell Genesys, Inc. (NASDAQ: CEGE). The company engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies. The company’s GVAX cancer Immunotherapies comprise Prostate Cancer, a phase III product for the treatment of prostate cancer; Pancreatic Cancer, a phase II product for pancreatic cancer; and Leukemia, a phase II product for the treatment of acute and chronic myelogenous leukemia, and myelodysplastic syndrome.
In the company’s recent news,
Cell Genesys announced that the U.S. Food and Drug Administration has placed an expected partial clinical hold on GVAX’s phase 3 program. The halt follows the company’s August 27, 2008 announcement which stated it would end the VITAL-2 phase 3 trial for GVAX.
Cell Genesys terminated the trial after its Independent Data Monitoring Committee (IDMC) observed an imbalance in deaths between two treatment arms of the VITAL-2 study, which compared GVAX immunotherapy in combination with Taxotere to Taxotere plus prednisone in patients with advanced prostate cancer.
In the announcement, Cell Genesys said the FDA confirmed that patients in the VITAL-1 phase 3 trial can continue to receive treatment after being notified of the observations found in VITAL-2. The FDA also agreed that patients enrolled in the recently terminated VITAL-2 trial may continue to receive Taxotere in the control arm, and as per investigator discretion in the investigational arm in place of combination therapy with GVAX immunotherapy plus Taxotere.
Cell Genesys does not expect observations to affect the outcome of the VITAL-1 trial; it expects the results of the VITAL-1 futility analysis in about a month. The company is also currently preparing to analyze the clinical data to determine the cause for the higher number of deaths observed in the GVAX plus Taxotere combination arm.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
